Statins News From Medical News TodayLatest Statins News From Medical News Today.New Pre-Clinical Research On RNAi-Mediated Silencing Of PCSK9, A Genetically Validated Regulator Of LDL Metabolism- August 14, 2008 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced that new pre-clinical data from its hypercholesterolemia program was published in Proceedings of the National Academy of Sciences (Frank-Kamenetsky, M., et al (August 11, 2008) Proc. Natl Acad. Sci. USA, 10.1073pnas.0805434105).http://www.medicalnewstoday.com/articles/118184.php Detailed Results From The SEAS Study To Be Presented At European Society Of Cardiology Congress 2008- August 11, 2008 Topline results from the SEAS trial, which were first disclosed publicly at a press conference in London on 21st July, have since then caused heated reaction. The results showed that reducing levels of LDL-cholesterol with a proprietary combination of simvastatin and ezetimibe in patients with aortic stenosis had no more effect on major cardiovascular events (the study's primary endpoint) than with placebo.http://www.medicalnewstoday.com/articles/117785.php Lipitor 80 Mg Reduced Heart Attack And Stroke Risk In Patients With Heart Disease, Type 2 Diabetes And Chronic Kidney Disease- August 8, 2008 Pfizer Inc announced that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor (atorvastatin calcium) 80 mg significantly reduced the risk of major cardiovascular events, including heart attack and stroke, by 35 percent compared with Lipitor 10 mg. This finding is from a subanalysis designed and completed following the closure of the five-year Treating to New Targets (TNT) study in patients with existing coronary heart disease.http://www.medicalnewstoday.com/articles/117637.php Karo Bio Announces Successful Phase II Study With Eprotirome In Combination With Statin- August 5, 2008 Karo Bio has successfully completed a 12 week phase IIb study of eprotirome (KB2115) given to patients with dyslipidemia (elevated blood lipids). These patients were already on statin treatment. Data show that eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein (a) and was safe and well tolerated.http://www.medicalnewstoday.com/articles/117177.php Nymox Has Global Patent Rights For Statin Drugs For The Treatment And Prevention Of Alzheimer's Disease- August 4, 2008 Nymox Pharmaceutical Corporation (NASDAQ:NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. An important new study has found that people who take statin drugs were about half as likely to develop dementia or clinically significant cognitive impairment as those who did not use statins (Neurology July 29, 2008; 71:344-355).http://www.medicalnewstoday.com/articles/117071.php |